NFKB1 and cardiac hypertrophy: It has been reported that the activation of ST2L has an anti-NF-κB effect, as in cardiomyocytes; IL-33-activated NF-κB inhibits angiotension II-induced NF-κB activation, thus alleviating the cardiac hypertrophy [62–64].